Profile: ACADIA Pharmaceuticals Inc (ACAD.O)
9 Dec 2016
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP).
The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.
Adrenergic and Muscarinic Programs
The Company, in collaboration with Allergan, has discovered small-molecule product candidates for the treatment of chronic pain. Its alpha adrenergic agonists provide pain relief in a range of preclinical models, without the side effects of the pain therapies, including sedation and cardiovascular and respiratory effects. Allergan has conducted various Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a visceral pain trial in patients that had hypersensitivity of the esophagus, and efficacy signals in approximately two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome.
The Company competes with Eisai Inc., Pfizer Inc., Actavis, Otsuka Pharmaceutical Co., Ltd., Sunovion Pharmaceuticals Inc. and Eli Lilly.
ACADIA Pharmaceuticals Inc
3611 Valley Centre Dr Ste 300
SAN DIEGO CA 92130-3331
Company Web Links
- BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin
- BRIEF-UK's CMA says accepted proposals in Acadia's Priory Group deal
- BRIEF-Acadia Pharmaceuticals initiates phase III trial of pimavanserin for adjunctive treatment in patients with Schizophrenia
- BRIEF-Acadia Pharmaceuticals initiates phase II study of pimavanserin in Alzheimer's disease agitation
- GM to add 650 jobs at Spring Hill factory to meet SUV demand